Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy Subjects

• Status: Completed
• Trial end date: 2015-03-01

Summary

This was a randomized, 2-period, 2-treatment-sequence crossover study to determine the relative bioavailability of pacritinib following administration as a 400 mg oral dose of four 100 mg pacritinib capsules and an 80 mg dose of an oral solution and to characterize the PK and major human metabolites of pacritinib.

• Phase: Phase 1

Details

• Lead Sponsor: CTI BioPharma
• Collaborator: Covance
• Treatments: Pharmaceutical Solutions